Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial
- PMID: 24119318
- DOI: 10.1016/j.eururo.2013.09.040
Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial
Abstract
Background: Prostate cancer is a key driver of cancer-related global disability-adjusted life-years. Androgen-deprivation therapy (ADT) for advanced disease is linked to fatigue, reduced physical function, and quality of life (QoL).
Objective: To evaluate the effect of a lifestyle intervention on disease-specific QoL, diastolic blood pressure, and cancer-related fatigue in sedentary men receiving long-term ADT for advanced prostate cancer.
Design, setting, and participants: A total of 100 hundred sedentary men with locally advanced or metastatic prostate cancer on long-term ADT were randomised to an intervention or usual care group.
Intervention: A 12-wk lifestyle intervention consisting of aerobic and resistance exercise with parallel dietary advice.
Outcome measurements and statistical analysis: Disease-specific QoL was measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaires at 12 wk postintervention and at 6 mo following withdrawal of support. Analysis of covariance and mixed regression were conducted.
Results and limitations: Clinically relevant improvements in FACT-P were seen at 12 wk in the intervention group compared with controls (mean difference: 8.9 points; 95% confidence interval [CI], 3.7-14.2; adjusted p=0.001). No difference was apparent at 6 mo (mean difference: 3.3 points; 95% CI, -2.6 to 9.3; adjusted p=0.27). No difference in diastolic blood pressure was seen at either follow-up (all p > 0.05). Clinically relevant improvements in FACT-F were seen at 12 wk (mean difference: 5.3 points; 95% CI, 2.7-7.9; adjusted p<0.001) and maintained following withdrawal of supervision (mean difference: 3.9 points; 95% CI, 1.1-6.8; adjusted p=0.007). Improvements in exercise tolerance and behaviour were maintained at 6 mo (adjusted p<0.001 and 0.038).
Conclusions: A lifestyle intervention resulted in a clinically meaningful improvement in disease-specific QoL that was not maintained postintervention. No effect on blood pressure occurred. Durability of response was seen in fatigue and exercise behaviour. Further evaluation of support structures is essential.
Trial registration: ISRCTN88605738.
Keywords: Androgen deprivation therapy; Diastolic blood pressure; Diet; Exercise; Fatigue; Prostate cancer; Quality of life.
Copyright © 2013. Published by Elsevier B.V.
Comment in
- 
  
  Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?Eur Urol. 2014 May;65(5):873-4. doi: 10.1016/j.eururo.2013.11.033. Epub 2013 Dec 2. Eur Urol. 2014. PMID: 24315708 No abstract available.
- 
  
  Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.Eur Urol. 2014 Sep;66(3):e51-2. doi: 10.1016/j.eururo.2014.04.018. Epub 2014 May 10. Eur Urol. 2014. PMID: 24813269 No abstract available.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        